Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
4237144 | Journal of Vascular and Interventional Radiology | 2016 | 11 Pages |
Abstract
The established size-based image biomarkers for tumor burden measurement continue to be applied to solid tumors, as size measurement can easily be used in clinical practice. However, in the setting of novel targeted therapies and liver-directed locoregional treatments for hepatocellular carcinoma (HCC), simple tumor anatomic changes can be less informative and usually appear later than biologic changes. Functional magnetic resonance (MR) imaging has the potential to be a promising technique for assessment of HCC response to therapy. Diffusion-weighted MR imaging is now widely used as a standard imaging modality to evaluate the liver. This review discusses the current clinical value of diffusion-weighted MR imaging in the evaluation of tumor response after nonsurgical locoregional treatment of HCC.
Keywords
ADCmRECISTEASLLRTSNREPIDWIHCCEuropean Association for the Study of the Liverechoplanar imagingdiffusion-weighted imagingRECISTlocoregional therapyWorld Health Organizationapparent diffusion coefficientRadiofrequencyResponse Evaluation Criteria in Solid Tumorsmodified Response Evaluation Criteria in Solid TumorsSignal-to-noise ratioHepatocellular carcinomaWHO
Related Topics
Health Sciences
Medicine and Dentistry
Radiology and Imaging
Authors
Zheng MD, Jian MD, Huan MD, Xiao-Dan MD, Li-Chao MD, Wen-Tao MD,